Analysis of BCR–ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2010-10, Vol.24 (10), p.1817-1821
Hauptverfasser:	Grant, H, Jiang, X, Stebbing, J, Foroni, L, Craddock, C, Griffiths, M, Clark, R E, O'Brien, S, Khorashad, J S, Gerrard, G, Wang, L, Irving, J A E, Wang, M, Karran, L, Dyer, M J S, Forrest, D, Page, K, Eaves, C J, Woolfson, A
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/737 692/699/67/1990/283/1896 Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Cancer Research Care and treatment Chronic myeloid leukemia Critical Care Medicine Drug Resistance, Neoplasm - genetics Fusion Proteins, bcr-abl - genetics Genetic aspects Genome, Human Hematologic and hematopoietic diseases Hematology Humans Imatinib Mesylate Intensive Internal Medicine Kinases letter-to-the-editor Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Medicine Medicine & Public Health Models, Theoretical Myeloid leukemia Oncology Phenotype Phenotypes Physiological aspects Piperazines - therapeutic use Point Mutation - genetics Prognosis Protein Structure, Tertiary Protein tyrosine kinase Pyrimidines - therapeutic use Risk factors Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!